APA (7th ed.) Citation

Métois, A., Bordeleau, M., Theret, L., Hajmirza, A., Moujaber, O., Spinella, J., . . . Sauvageau, G. (2025). IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia. Biomarker Research, 13(1), . https://doi.org/10.1186/s40364-025-00769-z

Chicago Style (17th ed.) Citation

Métois, Arnaud, et al. "IL1RAP Is an Immunotherapeutic Target for Normal Karyotype Triple-mutated Acute Myeloid Leukemia." Biomarker Research 13, no. 1 (2025). https://doi.org/10.1186/s40364-025-00769-z.

MLA (9th ed.) Citation

Métois, Arnaud, et al. "IL1RAP Is an Immunotherapeutic Target for Normal Karyotype Triple-mutated Acute Myeloid Leukemia." Biomarker Research, vol. 13, no. 1, 2025, https://doi.org/10.1186/s40364-025-00769-z.